{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:40:57Z","timestamp":1794271257674,"version":"4.9.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40257-025-00919-x","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:33:55Z","timestamp":1738575235000},"page":"251-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of Hydroxychloroquine: What a Dermatologist Should Know"],"prefix":"10.1007","volume":"26","author":[{"given":"Luca","family":"Rapparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-7864","authenticated-orcid":false,"given":"Stephano","family":"Cedirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"919_CR1","doi-asserted-by":"crossref","first-page":"1196783","DOI":"10.3389\/fphar.2023.1196783","volume":"14","author":"IH Yusuf","year":"2023","unstructured":"Yusuf IH, Charbel Issa P, Ahn SJ. Hydroxychloroquine-induced retinal toxicity. Front Pharmacol. 2023;14:1196783.","journal-title":"Front Pharmacol"},{"key":"919_CR2","unstructured":"Stokkermans TJ, Falkowitz DM, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Sep 8]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537086\/. Accessed 8 Sep 2024"},{"key":"919_CR3","unstructured":"US prescribing information: Plaquenil [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/009768s054lbl.pdf. Accessed 8 Sep 2024"},{"key":"919_CR4","unstructured":"go.drugbank.com: Hydroxychloroquine. [Internet]. [cited 2024 Sep 8]. Available from: https:\/\/go.drugbank.com\/drugs\/DB01611. Accessed 8 Sep 2024"},{"issue":"3","key":"919_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.122.001018","volume":"51","author":"MN Paludetto","year":"2023","unstructured":"Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293\u2013305.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"919_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"919_CR7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.117.245639","volume":"365","author":"KP Collins","year":"2018","unstructured":"Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447\u201359.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"919_CR8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","volume":"46","author":"T Munster","year":"2002","unstructured":"Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"919_CR9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/rheumatology\/keaa592","volume":"60","author":"NW Andersson","year":"2021","unstructured":"Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology. 2021;60(5):2317\u201326.","journal-title":"Rheumatology"},{"issue":"4","key":"919_CR10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.42015","volume":"74","author":"CD Chambers","year":"2022","unstructured":"Chambers CD, Johnson DL, Xu R, Luo Y, Felix R, Fine M, et al. Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study. Arthritis Rheumatol. 2022;74(4):711\u201324.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"919_CR11","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2020.09.007","volume":"224","author":"KF Huybrechts","year":"2021","unstructured":"Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol. 2021;224(3):290.e1-290.e22.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"919_CR12","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S2665-9913(23)00215-1","volume":"5","author":"K Schreiber","year":"2023","unstructured":"Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet Rheumatology. 2023;5(9):e501\u20136.","journal-title":"The Lancet Rheumatology."},{"issue":"2","key":"919_CR13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/rheumatology\/kead384","volume":"63","author":"MD Russell","year":"2024","unstructured":"Russell MD, Dey M, Flint J, Davie P, Allen A, Crossley A, et al. British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine. Rheumatology. 2024;63(2):e37\u20138.","journal-title":"Rheumatology"},{"issue":"3","key":"919_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.10456","volume":"47","author":"D Erkan","year":"2002","unstructured":"Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. Arthritis Rheum. 2002;47(3):285\u201390.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"919_CR15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"919_CR16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41584-022-00868-3","volume":"19","author":"T Lenfant","year":"2023","unstructured":"Lenfant T, Costedoat-Chalumeau N. Hydroxychloroquine dose: balancing toxicity and SLE flare risk. Nat Rev Rheumatol. 2023;19(1):6\u20137.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"919_CR17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11310780-000000000-00000","volume":"10","author":"HW Walling","year":"2009","unstructured":"Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365\u201381.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"919_CR18","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/medicina59112022","volume":"59","author":"KA Englert","year":"2023","unstructured":"Englert KA, Dyduch G, K\u0142osowicz A, Spa\u0142kowska M, Jaworek AK, Migacz-Gruszka K, et al. Cutaneous toll-like receptor 9 pre-defines hydroxychloroquine dosage in patients with both discoid and subacute lupus erythematosus. Medicina. 2023;59(11):2022.","journal-title":"Medicina"},{"issue":"3","key":"919_CR19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/BOR.0000000000000704","volume":"32","author":"H Shi","year":"2020","unstructured":"Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208\u201314.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"919_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00128071-200607030-00003","volume":"7","author":"JM Tripp","year":"2006","unstructured":"Tripp JM, Maibach HI. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Am J Clin Dermatol. 2006;7(3):171\u20135.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"919_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2021.07.038","volume":"87","author":"G Sonigo","year":"2022","unstructured":"Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, et al. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: a retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2022;87(1):203\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"919_CR22","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/jdv.15771","volume":"33","author":"H Husein-ElAhmed","year":"2019","unstructured":"Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. Acad Dermatol Venereol. 2019;33(10):1847\u201362.","journal-title":"Acad Dermatol Venereol"},{"issue":"1","key":"919_CR23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40257-015-0160-6","volume":"17","author":"L Atzmony","year":"2016","unstructured":"Atzmony L, Reiter O, Hodak E, Gdalevich M, Mimouni D. Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am J Clin Dermatol. 2016;17(1):11\u201322.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"919_CR24","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1111\/odi.14746","volume":"30","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xu H, Li C, Wang Y, Lu R, Hua H, et al. Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial. Oral Dis. 2024;30(5):3126\u201335.","journal-title":"Oral Dis"},{"issue":"2","key":"919_CR25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/jdv.15372","volume":"33","author":"M Starace","year":"2019","unstructured":"Starace M, Brandi N, Alessandrini A, Bruni F, Piraccini BM. Frontal fibrosing alopecia: a case series of 65 patients seen in a single Italian centre. Acad Dermatol Venereol. 2019;33(2):433\u20138.","journal-title":"Acad Dermatol Venereol"},{"issue":"3","key":"919_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40257-019-00424-y","volume":"20","author":"M Iorizzo","year":"2019","unstructured":"Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019;20(3):379\u201390.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"919_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2009.08.054","volume":"62","author":"C Chiang","year":"2010","unstructured":"Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"919_CR28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s13555-024-01186-0","volume":"14","author":"M Starace","year":"2024","unstructured":"Starace M, Cedirian S, Rapparini L, Quadrelli F, Pampaloni F, Bruni F, et al. Enhanced insights into frontal fibrosing alopecia: advancements in pathogenesis understanding and management strategies. Dermatol Ther (Heidelb). 2024;14(6):1457\u201377.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"919_CR29","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12463","volume":"30","author":"E Nic Dhonncha","year":"2017","unstructured":"Nic Dhonncha E, Foley CC, Markham T. The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review. Dermatol Ther. 2017;30(3): e12463.","journal-title":"Dermatol Ther"},{"issue":"2","key":"919_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","volume":"82","author":"R Waldman","year":"2020","unstructured":"Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283\u201396.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"919_CR31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339\u201353.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"919_CR32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2019.01.004","volume":"128","author":"AK Singal","year":"2019","unstructured":"Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128(3):271\u201381.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"919_CR33","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","volume":"10","author":"AK Singal","year":"2012","unstructured":"Singal AK, Kormos-Hallberg C, Lee C, Sadagoparamanujam VM, Grady JJ, Freeman DH, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10(12):1402\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"919_CR34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/07853890.2020.1839959","volume":"53","author":"P Bansal","year":"2021","unstructured":"Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117\u201334.","journal-title":"Ann Med"},{"issue":"6","key":"919_CR35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386\u201394.","journal-title":"Ophthalmology"},{"issue":"7","key":"919_CR36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology. 2003;110(7):1321\u20136.","journal-title":"Ophthalmology"},{"issue":"6","key":"919_CR37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775\u201384.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"919_CR38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415\u201322.","journal-title":"Ophthalmology"},{"issue":"12","key":"919_CR39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"919_CR40","first-page":"294","volume":"12","author":"JCS Yam","year":"2006","unstructured":"Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294\u2013304.","journal-title":"Hong Kong Med J"},{"key":"919_CR41","unstructured":"Lang GK. Ophthalmology: a short textbook. Stuttgart New York: Thieme; 2007. 586 p. (Thieme flexibook)."},{"issue":"6","key":"919_CR42","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","volume":"122","author":"DH Lee","year":"2015","unstructured":"Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122(6):1252\u20136.","journal-title":"Ophthalmology"},{"issue":"1","key":"919_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(83)91267-6","volume":"75","author":"HN Bernstein","year":"1983","unstructured":"Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1):25\u201334.","journal-title":"Am J Med"},{"issue":"6","key":"919_CR44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/art.41683","volume":"73","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis & Rheumatology. 2021;73(6):908\u201311.","journal-title":"Arthritis & Rheumatology."},{"issue":"1","key":"919_CR45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis & Rheumatology. 2016;68(1):184\u201390.","journal-title":"Arthritis & Rheumatology."},{"issue":"5","key":"919_CR46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.10677","volume":"7","author":"AM Jorge","year":"2024","unstructured":"Jorge AM, Melles RB, Marmor MF, Zhou B, Zhang Y, Choi HK. Risk factors for hydroxychloroquine retinopathy and its subtypes. JAMA Netw Open. 2024;7(5): e2410677.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"919_CR47","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1167\/iovs.05-1290","volume":"47","author":"U Kellner","year":"2006","unstructured":"Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine\/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8):3531\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"919_CR48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0161-6420(02)01168-5","volume":"109","author":"MF Marmor","year":"2002","unstructured":"Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109(7):1377\u201382.","journal-title":"Ophthalmology"},{"issue":"7","key":"919_CR49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ophtha.2021.02.015","volume":"128","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, et al. Collaboration for the management of hydroxychloroquine. Ophthalmology. 2021;128(7):1115\u20136.","journal-title":"Ophthalmology"},{"issue":"9","key":"919_CR50","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamadermatol.2021.2699","volume":"157","author":"N Fett","year":"2021","unstructured":"Fett N, Werth VP. A Multidisciplinary collaborative approach to retinal toxic effects screening for dermatology patients taking antimalarials. JAMA Dermatol. 2021;157(9):1112.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"919_CR51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/eye.2016.298","volume":"31","author":"IH Yusuf","year":"2017","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye. 2017;31(6):828\u201345.","journal-title":"Eye"},{"issue":"3","key":"919_CR52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10633-010-9220-7","volume":"120","author":"P Salu","year":"2010","unstructured":"Salu P, Uvijls A, Van Den Brande P, Leroy BP. Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. Doc Ophthalmol. 2010;120(3):251\u201364.","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"919_CR53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0049-0172(10)80009-5","volume":"23","author":"M Easterbrook","year":"1993","unstructured":"Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arthritis Rheum. 1993;23(2):62\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"919_CR54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","volume":"62","author":"MB Raizman","year":"2017","unstructured":"Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62(3):286\u2013301.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"919_CR55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780130108","volume":"13","author":"ML Rubin","year":"1970","unstructured":"Rubin ML, Thomas WC. Diplopia and loss of accommodation due to chloroquine. Arthritis Rheum. 1970;13(1):75\u201382.","journal-title":"Arthritis Rheum"},{"issue":"13","key":"919_CR56","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","volume":"67","author":"PJ Schwartz","year":"2016","unstructured":"Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"919_CR57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11897-020-00485-9","volume":"17","author":"M Gatti","year":"2020","unstructured":"Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A, et al. The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia. Curr Heart Fail Rep. 2020;17(6):365\u201383.","journal-title":"Curr Heart Fail Rep"},{"issue":"4","key":"919_CR58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000531132","volume":"148","author":"X Wang","year":"2023","unstructured":"Wang X, Feng Y, Liu S, Liu J, Pan S, Wei L, et al. Hydroxychloroquine attenuates hERG channel by promoting the membrane channel degradation: computational simulation and experimental evidence for QT-interval prolongation with hydroxychloroquine treatment. Cardiology. 2023;148(4):310\u201323.","journal-title":"Cardiology"},{"issue":"458","key":"919_CR59","volume":"30","author":"R Yu","year":"2021","unstructured":"Yu R, Li P. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021;30(458):152822.","journal-title":"Toxicology"},{"issue":"915","key":"919_CR60","volume":"15","author":"V Ballet","year":"2022","unstructured":"Ballet V, Bohme GA, Brohan E, Boukaiba R, Chambard JM, Angouillant-Boniface O, et al. In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. Eur J Pharmacol. 2022;15(915): 174670.","journal-title":"Eur J Pharmacol"},{"issue":"913","key":"919_CR61","volume":"15","author":"U Thomet","year":"2021","unstructured":"Thomet U, Amuzescu B, Knott T, Mann SA, Mubagwa K, Radu BM. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. Eur J Pharmacol. 2021;15(913): 174632.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"919_CR62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.120.000484","volume":"377","author":"M Szendrey","year":"2021","unstructured":"Szendrey M, Guo J, Li W, Yang T, Zhang S. COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels. J Pharmacol Exp Ther. 2021;377(2):265\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"919_CR63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/imj.15908","volume":"53","author":"JL Fairley","year":"2023","unstructured":"Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, et al. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Intern Med J. 2023;53(3):311\u20137.","journal-title":"Intern Med J"},{"issue":"10","key":"919_CR64","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00228-021-03133-w","volume":"77","author":"DM Saint-Gerons","year":"2021","unstructured":"Saint-Gerons DM, Tabar\u00e9s-Seisdedos R. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol. 2021;77(10):1513\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"919_CR65","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/bcp.14546","volume":"87","author":"A Goldman","year":"2021","unstructured":"Goldman A, Bomze D, Dankner R, Hod H, Meirson T, Boursi B, et al. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: a comprehensive pharmacovigilance analysis of pre-COVID-19 reports. Br J Clin Pharmacol. 2021;87(3):1432\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"919_CR66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.sapharm.2020.04.016","volume":"17","author":"A Sarayani","year":"2021","unstructured":"Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021;17(2):483\u20136.","journal-title":"Res Social Adm Pharm"},{"issue":"12","key":"919_CR67","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/pds.5155","volume":"29","author":"PS Nishtala","year":"2020","unstructured":"Nishtala PS, Gill S, Chyou TY. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. Pharmacoepidemiol Drug Saf. 2020;29(12):1689\u201395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"919_CR68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.120.048238","volume":"142","author":"LS Nguyen","year":"2020","unstructured":"Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database. Circulation. 2020;142(3):303\u20135.","journal-title":"Circulation"},{"issue":"9","key":"919_CR69","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1111\/ijd.16660","volume":"62","author":"O Ezemma","year":"2023","unstructured":"Ezemma O, Devjani S, Jothishankar B, Kelley KJ, Senna MM. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023;62(9):e473\u20134.","journal-title":"Int J Dermatol"},{"issue":"24","key":"919_CR70","first-page":"00911","volume":"S0190\u20139622","author":"CE Obijiofor","year":"2024","unstructured":"Obijiofor CE, Sikora M, Liu L, Stern MJ, Hena KM, Mazori DR, et al. Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: a multicenter retrospective study. J Am Acad Dermatol. 2024;S0190\u20139622(24):00911\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"919_CR71","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaad.2022.05.023","volume":"88","author":"M Collins","year":"2023","unstructured":"Collins M, Ali S, Wiss IP, Senna MM. Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia. J Am Acad Dermatol. 2023;88(2):434\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"919_CR72","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.41934","volume":"73","author":"J Desmarais","year":"2021","unstructured":"Desmarais J, Rosenbaum JT, Costenbader KH, Ginzler EM, Fett N, Goodman S, et al. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021;73(12):2151\u201360.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"919_CR73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479\u201387.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"919_CR74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","volume":"7","author":"JE Tisdale","year":"2014","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381\u201390.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6\u20137","key":"919_CR75","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annder.2018.03.168","volume":"145","author":"P T\u00e9tu","year":"2018","unstructured":"T\u00e9tu P, Hamelin A, Lebrun-Vignes B, Soria A, Barbaud A, Franc\u00e8s C, et al. Pr\u00e9valence des effets ind\u00e9sirables de l\u2019hydroxychloroquine (Plaquenil \u00ae ) dans une population dermatologique\u202f: \u00e9tude r\u00e9trospective sur 102 patients. Ann Dermatol Venereol. 2018;145(6\u20137):395\u2013404.","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"919_CR76","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.55563\/clinexprheumatol\/styx9u","volume":"39","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021;39(5):1099\u2013107.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"919_CR77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2020.04.024","volume":"83","author":"AN Sharma","year":"2020","unstructured":"Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563\u201378.","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"919_CR78","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2169\/internalmedicine.5042-20","volume":"59","author":"Y Hosokawa","year":"2020","unstructured":"Hosokawa Y, Oiwa H. Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese Municipal Hospital. Intern Med. 2020;59(20):2485\u201390.","journal-title":"Intern Med"},{"issue":"3","key":"919_CR79","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/15321819.2024.2350544","volume":"45","author":"B Zamani","year":"2024","unstructured":"Zamani B, Hasan-Abad AM, Rafizadeh SM, Akbari H, Motedayyen H. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous. J Immunoassay Immunochem. 2024;45(3):178\u201388.","journal-title":"J Immunoassay Immunochem"},{"issue":"7","key":"919_CR80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1346-8138.17177","volume":"51","author":"A Teboul","year":"2024","unstructured":"Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: what dermatologists should know. J Dermatol. 2024;51(7):895\u2013903.","journal-title":"J Dermatol"},{"issue":"8","key":"919_CR81","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/1346-8138.14512","volume":"45","author":"C Kishi","year":"2018","unstructured":"Kishi C, Motegi S, Yasuda M, Ishikawa O. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic\/cutaneous lupus erythematosus patients. J Dermatol. 2018;45(8):1020\u20132.","journal-title":"J Dermatol"},{"issue":"4","key":"919_CR82","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/000155599750010850","volume":"79","author":"SA Holme","year":"1999","unstructured":"Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol. 1999;79(4):333\u2013333.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"919_CR83","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0190-9622(03)02733-6","volume":"50","author":"CC Evans","year":"2004","unstructured":"Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol. 2004;50(4):650\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"919_CR84","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.clinthera.2008.05.014","volume":"30","author":"A Paradisi","year":"2008","unstructured":"Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther. 2008;30(5):930\u201340.","journal-title":"Clin Ther"},{"issue":"8","key":"919_CR85","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/jocd.14603","volume":"21","author":"G Wang","year":"2022","unstructured":"Wang G, Zhuo N, Li J. Acute generalized exanthematous pustulosis induced by generic hydroxychloroquine. J of Cosmetic Dermatology. 2022;21(8):3608\u201310.","journal-title":"J of Cosmetic Dermatology."},{"issue":"12","key":"919_CR86","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10067-009-1262-4","volume":"28","author":"A Lateef","year":"2009","unstructured":"Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol. 2009;28(12):1449\u201352.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"919_CR87","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/20009666.2018.1547089","volume":"8","author":"C Mercogliano","year":"2018","unstructured":"Mercogliano C, Khan M, Lin C, Mohanty E, Zimmerman R. AGEP overlap induced by hydroxychloroquine: a case report and literature review. J Community Hosp Intern Med Perspect. 2018;8(6):360\u20132.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"1","key":"919_CR88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13256-020-02504-8","volume":"14","author":"I Coleman","year":"2020","unstructured":"Coleman I, Ruiz G, Brahmbhatt S, Ackerman L. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. J Med Case Rep. 2020;14(1):210.","journal-title":"J Med Case Rep"},{"issue":"3","key":"919_CR89","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/idoj.IDOJ_280_20","volume":"11","author":"K Sardana","year":"2020","unstructured":"Sardana K, Sinha S, Sachdeva S. Hydroxychloroquine in dermatology and beyond: Recent update. Indian Dermatol Online J. 2020;11(3):453.","journal-title":"Indian Dermatol Online J"},{"key":"919_CR90","doi-asserted-by":"crossref","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.24748.1","volume":"9","author":"A Hasegawa","year":"2020","unstructured":"Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:F1000 Faculty Rev-612.","journal-title":"F1000Res"},{"issue":"6","key":"919_CR91","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","volume":"38","author":"MH Noe","year":"2020","unstructured":"Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Clin Dermatol. 2020;38(6):607\u201312.","journal-title":"Clin Dermatol"},{"issue":"5","key":"919_CR92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaad.2015.08.008","volume":"73","author":"RP Dodiuk-Gad","year":"2015","unstructured":"Dodiuk-Gad RP, Olteanu C, Jeschke MG, Cartotto R, Fish J, Shear NH. Treatment of toxic epidermal necrolysis in North America. J Am Acad Dermatol. 2015;73(5):876-877.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"919_CR93","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10067-007-0772-1","volume":"27","author":"A Volpe","year":"2008","unstructured":"Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol. 2008;27(4):537\u20139.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"919_CR94","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","volume":"10","author":"N Hama","year":"2022","unstructured":"Hama N, Abe R, Gibson A, Phillips EJ. Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-1167.e5.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"919_CR95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0036933018763277","volume":"63","author":"A Randhawa","year":"2018","unstructured":"Randhawa A, Wylie G. A case of an acute cutaneous drug reaction with hydroxychloroquine. Scott Med J. 2018;63(3):91\u20134.","journal-title":"Scott Med J"},{"issue":"19","key":"919_CR96","first-page":"6003","volume":"25","author":"G Papazisis","year":"2021","unstructured":"Papazisis G, Siafis S, Cepatyte D, Giannis D, Stamoula E, Tzachanis D, et al. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database. Eur Rev Med Pharmacol Sci. 2021;25(19):6003\u201312.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"919_CR97","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101812","volume":"36","author":"K Eljaaly","year":"2020","unstructured":"Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. Hydroxychloroquine safety: a meta-analysis of randomized controlled trials. Travel Med Infect Dis. 2020;36: 101812.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"919_CR98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/0961203318812685","volume":"28","author":"S Zhang","year":"2019","unstructured":"Zhang S, Liu X, Cai L, Zhang J, Zhou C. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. Lupus. 2019;28(1):129\u201332.","journal-title":"Lupus"},{"issue":"4","key":"919_CR99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00128071-200607040-00006","volume":"7","author":"SM Herman","year":"2006","unstructured":"Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol. 2006;7(4):249\u201357.","journal-title":"Am J Clin Dermatol"},{"issue":"16","key":"919_CR100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.5694\/j.1326-5377.1962.tb20626.x","volume":"2","author":"JF Drew","year":"1962","unstructured":"Drew JF. Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic disease. Med J Aust. 1962;2(16):618\u201320.","journal-title":"Med J Aust"},{"issue":"5","key":"919_CR101","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10787-018-0498-5","volume":"26","author":"A Mascolo","year":"2018","unstructured":"Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018;26(5):1141\u20139.","journal-title":"Inflammopharmacology"},{"issue":"4","key":"919_CR102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2190\/8DRE-DBNH-MXXG-7AJF","volume":"23","author":"S Akhtar","year":"1993","unstructured":"Akhtar S, Mukherjee S. Chloroquine induced mania. Int J Psychiatry Med. 1993;23(4):349\u201356.","journal-title":"Int J Psychiatry Med"},{"issue":"2","key":"919_CR103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.genhosppsych.2013.07.012","volume":"36","author":"PS Biswas","year":"2014","unstructured":"Biswas PS, Sen D, Majumdar R. Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. Gen Hosp Psychiatry. 2014;36(2):181\u20136.","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"919_CR104","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/10600280221113572","volume":"57","author":"F Talarico","year":"2023","unstructured":"Talarico F, Chakravarty S, Liu YS, Greenshaw AJ, Passos IC, Cao B. Systematic review of psychiatric adverse effects induced by chloroquine and hydroxychloroquine: case reports and population studies. Ann Pharmacother. 2023;57(4):463\u201379.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"919_CR105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.comppsych.2013.05.010","volume":"54","author":"N Pinho de Oliveira Ribeiro","year":"2013","unstructured":"Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54(8):1185\u20139.","journal-title":"Compr Psychiatry"},{"issue":"2","key":"919_CR106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5582\/bst.2020.03082","volume":"14","author":"K Sato","year":"2020","unstructured":"Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends. 2020;14(2):139\u201343.","journal-title":"Biosci Trends"},{"issue":"3","key":"919_CR107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jgh3.12258","volume":"4","author":"LT de Moraes Falc\u00e3o","year":"2020","unstructured":"de Moraes Falc\u00e3o LT, Terrabuio DRB, Diniz MA, da Silva Evangelista A, Souza FG, Cancado REL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open. 2020;4(3):371\u20137.","journal-title":"JGH Open."},{"issue":"3","key":"919_CR108","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/pubmed\/fdaa074","volume":"42","author":"BS Nagaraja","year":"2020","unstructured":"Nagaraja BS, Ramesh KN, Dhar D, Mondal MS, Dey T, Saha S, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events\u2019 analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Oxf). 2020;42(3):493\u2013503.","journal-title":"J Public Health (Oxf)"},{"issue":"7","key":"919_CR109","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1093\/rheumatology\/keaa771","volume":"60","author":"JCE Lane","year":"2021","unstructured":"Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). 2021;60(7):3222\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"919_CR110","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","volume":"34","author":"GA Horne","year":"2020","unstructured":"Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020;34(7):1775\u201386.","journal-title":"Leukemia"},{"issue":"12","key":"919_CR111","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/14740338.2020.1830058","volume":"19","author":"EL Giraud","year":"2020","unstructured":"Giraud EL, Jessurun NT, van Hunsel FPAM, van Puijenbroek EP, van Tubergen A, Ten Klooster PM, et al. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opin Drug Saf. 2020;19(12):1617\u201324.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"919_CR112","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40264-020-01013-3","volume":"43","author":"P Garcia","year":"2020","unstructured":"Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric disorders and hydroxychloroquine for coronavirus disease 2019 (COVID-19): a VigiBase study. Drug Saf. 2020;43(12):1315\u201322.","journal-title":"Drug Saf"},{"issue":"3","key":"919_CR113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CMR.0000000000000821","volume":"32","author":"G Awada","year":"2022","unstructured":"Awada G, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, Neyns B. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-\/MEK-inhibitors and immune checkpoint inhibitors. Melanoma Res. 2022;32(3):183\u201391.","journal-title":"Melanoma Res"},{"issue":"03","key":"919_CR114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-0032-1327626","volume":"38","author":"B Plesnicar","year":"2013","unstructured":"Plesnicar B, Velikonja I, Plesnicar A, Vitorovic S. Two challenge and rechallenge episodes of chloroquine-induced psychotic mania in a patient with rheumatoid arthritis. Akt Rheumatol. 2013;38(03):177\u20139.","journal-title":"Akt Rheumatol."},{"issue":"8","key":"919_CR115","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/ggi.12490","volume":"15","author":"YT Kwak","year":"2015","unstructured":"Kwak YT, Yang Y, Park SY. Chloroquine-associated psychosis mimicking very late-onset schizophrenia: case report. Geriatr Gerontol Int. 2015;15(8):1096\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"1","key":"919_CR116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40800-017-0048-x","volume":"4","author":"C Manzo","year":"2017","unstructured":"Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with hydroxychloroquine. Drug Saf Case Rep. 2017;4(1):6.","journal-title":"Drug Saf Case Rep."},{"issue":"1","key":"919_CR117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","volume":"78","author":"L Mittal","year":"2018","unstructured":"Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78(1):100-106.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"919_CR118","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0190-9622(85)70109-0","volume":"12","author":"WQ Ward","year":"1985","unstructured":"Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12(5 Pt 1):863\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"919_CR119","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0151-9638(04)93642-3","volume":"131","author":"V Ferraro","year":"2004","unstructured":"Ferraro V, Mantoux F, Denis K, Lay-Macagno MA, Ortonne JP, Lacour JP. Hallucinations au cours d\u2019un traitement par hydroxychloroquine. Ann Dermatol Venereol. 2004;131(5):471\u20133.","journal-title":"Ann Dermatol Venereol"},{"issue":"03","key":"919_CR120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5414\/CP203789","volume":"59","author":"Z Ganjei","year":"2021","unstructured":"Ganjei Z, Bahmani K. A case report of hydroxychloroquine-induced auditory and visual hallucination. Int J Clin Pharmacol Ther. 2021;59(03):254\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"919_CR121","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284\u201390.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"919_CR122","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","volume":"73","author":"M Petri","year":"2021","unstructured":"Petri M, Konig MF, Li J, Goldman DW. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(6):997\u20131004.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"919_CR123","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cpt.885","volume":"103","author":"N Costedoat-Chalumeau","year":"2018","unstructured":"Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018;103(6):1074\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"919_CR124","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","volume":"72","author":"M Petri","year":"2020","unstructured":"Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis & Rheumatol. 2020;72(3):448\u201353.","journal-title":"Arthritis & Rheumatol"},{"issue":"12","key":"919_CR125","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/rheumatology\/keaa157","volume":"59","author":"T Lenfant","year":"2020","unstructured":"Lenfant T, Salah S, Leroux G, Bousquet E, Le Guern V, Chasset F, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford). 2020;59(12):3807\u201316.","journal-title":"Rheumatology (Oxford)"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00919-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:26:59Z","timestamp":1740385619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00919-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00919-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"8 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Alma Mater Studiorum - Universit\u00e0 di Bologna within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors participated equally in the drafting of the manuscript. All authors read and approved the final paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"All authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval; Patient Consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}